Eli Lilly Launches TuneLab to Give Biotechs Access to AI Models
The new platform provides access to drug discovery models trained on over $1 billion of Lilly's proprietary preclinical and safety data.
Democratizing Drug Discovery
Pharmaceutical company Eli Lilly and Company on September 9, 2025, launched Lilly TuneLab, a new artificial intelligence platform designed to give biotechnology companies access to its advanced drug discovery models. The company stated the models are trained on its proprietary preclinical and safety datasets, which were obtained at a cost of over $1 billion.
"Lilly TuneLab was created to be an equalizer so that smaller companies can access some of the same AI capabilities used every day by Lilly scientists,” said Daniel Skovronsky, Lilly’s chief scientific officer, in the announcement. The platform is part of Lilly's …
Archive Access
This article is older than 24 hours. Create a free account to access our 7-day archive.